Introduction
The replication-deficient recombinant adenovirus vector (rAd) has significant potential utility for gene transfer to several tissues. 1 Skeletal muscle is an excellent target for rAd-mediated gene therapy, [2] [3] [4] and rAd has delivered therapeutic genes efficiently to neonatal muscle. 5 However, the rAd-mediated gene transfer to skeletal muscle has been criticized for two problems: the limited expression of the transgene and the poor tropism of adenovirus for mature skeletal muscle fibers. The former is due to an immune response induced by adenoviral gene products 6 and to down-regulation of the transgene expression. Some researchers have reported that immune reaction to rAd has been suppressed by FK506 immunosuppression agent, 7 CTLA4Ig, 8 and a gutted adenovirus vector. [9] [10] [11] Thus, repetitive transduction to skeletal muscle could seem valid for consecutive expression of a therapeutic gene. The latter is caused by a maturation-dependent loss of the myofiber's susceptibility to rAd uptake which is due to structural and biochemical changes during muscle maturation. 5, [12] [13] [14] When an adenovirus particle enters a target cell, two types of receptor-mediated process are involved. First, the fiber knob of the adenovirus capsid binds to the attachment receptor on the cell surface, such as a Coxsackie B and adenovirus receptor (CAR) [15] [16] [17] [18] and a MHC class I ␣2 domain. 19 The CAR has been reported as a 46 kDa transmembrane protein and hCAR cDNA and LacZ gene. Subsequent infection by recombinant adenovirus containing the marker gene, green fluorescence protein, became efficient even at a low MOI of 25. Thus, elevated hCAR expression in mouse muscle fibers made a second virus inoculation at low doses possible. We also demonstrated that the elevated hCAR expression did not influence muscle membrane integrity. Our results suggest that co-expression of CAR and a therapeutic gene by adenovirus vector constitutes a novel strategy to advance gene therapy for hereditary muscle diseases. Gene Therapy (2001) 8, 20-27. suggests a high-affinity attachment receptor.
14 This is followed by binding of the penton base to low-affinity internalization receptors, such as ␣ v ␤ 3 , ␣ v ␤ 5 and ␣ 5 ␤ 1 integrins, [20] [21] [22] which results in internalization of virus capsids. 23 Thus, the densities of attachment and internalization receptors on target cells influence their susceptibility to adenoviral infection. 5, 14, 21 Although MHC levels were not developmentally regulated, CAR expression was severely down-regulated during muscle maturation. 14 The lack of expression of CAR may limit the efficacy of rAd-mediated gene transfer to mature muscle fibers. Here, we show that the rAd-mediated CAR expression enhances efficacy of a second rAd-mediated gene transfer, and we suggest a possibility of repetitive transduction of therapeutic gene to mature skeletal muscle fiber in vivo.
Results
Efficient second gene transduction after rAd-mediated CAR transfer to C2C12 myoblasts and myofibers To examine whether repetitive gene transfer to muscle cell after rAd-mediated CAR expression was possible, we initially used C2C12 myoblasts and myotubes for in vitro study. The C2C12 cells used in this study expressed low levels of mouse CAR (mCAR) as checked by RT-PCR (data not shown), and a high dose of rAd was then inoculated. Since AdCMVhCAR-LacZ encodes human CAR (hCAR) cDNA and the LacZ gene under the control of a cytomegalovirus (CMV) enhancer/promoter, each product must co-localize in each infected cell. In cytological analysis, CAR expressing cells were identified by X-gal staining. ␤-Galactosidase was barely expressed following transduction by AdCMVhCAR-LacZ in C2C12 myoblasts and myotubes at a MOI of 250 and 90 min inoculation time. However, once the cells were transduced by the AdCMVhCAR-LacZ, second gene transduction by AdCMVGFPS65T or AdRSVEGFP became efficient even at a MOI of 25 (Figure 1a, b) . In contrast, there was no detectable GFP expression in the AdCMVLacZ-infected or uninfected C2C12 cells (data not shown). We then quantitatively analyzed the efficiency of the rAdmediated hCAR expression following the second rAd containing GFP infection, using fluorocytometry to detect GFP and hCAR-positive cells (Figure 1c ). The expression of hCAR was directly detected by using an anti-hCAR monoclonal antibody (RmcB). 15 The percentage of GFPpositive cells in the total cells was nearly 70%, while in the hCAR-positive cell group it was over 90%. In the control group, GFP-positive cells were less than 1%. Since the P value was Ͻ0.0001, this was considered extremely significant ( Figure 1d ). Furthermore, we met with the same result when used AdRSVEGFP as a second marker virus and anti-hCAR polyclonal antibody (data not shown). 24 We concluded that AdCMVhCAR-LacZ rendered C2C12 myoblasts and myotubes sensitive for a second rAd inoculation.
Repetitive and efficient gene transduction by rAdmediated hCAR cDNA transfer to mouse skeletal muscle To evaluate the efficacy of elevated expression of hCAR in vivo, the nude mice were selected in order to prevent the second rAd, AdRSVEGFP, from being eliminated by the host immune system. The reason why we did not use AdCMVGFPS65T was to avoid the effect of the promoter competition. The same virus titer (1 × 10 8 p.f.u.) of AdCMVhCAR-LacZ or AdCMVLacZ was inoculated into the bilateral antero-tibialis muscles in each animal at post-natal day 7. Seven days after the first inoculation 2 × 10 7 p.f.u. of the second AdRSVEGFP was inoculated at the same site as the first injection. Expression of ␤-galactosidase, which was the first transduction marker, was detected in about 50% of the antero-tibialis muscle fibers in both groups. The expression of the second marker gene, GFP, was detected in about 45% of the fibers expressing hCAR and LacZ (Figure 2a, c) . In contrast, a few fibers expressed faint GFP signal in the AdCMVLacZ pre-injected group (Figure 2b, d ). There was a significant difference between these two groups (P Ͻ 0.001, Figure 2e ).
To confirm the utility of this method in more mature muscle, we injected 2.4 × 10 7 p.f.u. of AdRSVEGFP as a second maker virus 4 weeks after the first inoculation. In this condition, GFP expression was only seen in anterotibialis muscle pre-injected with AdCMVhCAR-LacZ. In Figure 3b and c, some fibers are stained with X-gal strongly, which meant much hCAR expression, and also showed a high level expression of GFP. In contrast, a few fibers expressing faint GFP signal were detected in antero-tibialis muscles pre-injected with AdCMVLacZ (Figure 3b and d) . These results showed that this method of expressing hCAR by rAd was applicable for gene transduction not only to immature but also to more mature muscle.
Gene Therapy
Influence of elevated hCAR expression on mouse muscle membrane We next examined whether elevated hCAR produced any influence on mouse muscle membrane. Serial sections from antero-tibialis muscles inoculated with AdCMVhCAR-LacZ and AdRSVEGFP, AdCMVLacZ and AdRSVEGFP, or not treated, were stained with three first antibodies: anti-hCAR antibody, 24 anti-dystrophin antibody, 25 or anti-␤-dystroglycan antibody, respectively ( Figure 4 ). The hCAR was located on plasma membranes of many muscle fibers infected with AdCMVhCAR-LacZ (Figure 4b and p). The strong signal was detected in the cytosol of some fibers infected with many AdCMVhCARLacZ. They showed that overexpressed hCAR appeared to exist not only on plasma membrane but also at the Golgi apparatus or endplasmic reticulum in cytosol at highly magnified views (1:4000, Figure 4p and q). Since there were no data concerning the biological role of CAR in skeletal muscle, we thought that the elevated expression of exogenous CAR in skeletal muscle might disturb the integrity of membrane-related proteins. We therefore examined histologically for localization of dystrophin and its related protein, ␤-dystroglycan, and found that they were localized at sub-sarcolemma of myofibers infected with AdCMVhCAR-LacZ. There were no detectable differences in the presence of dystrophin and ␤-dystroglycan along the plasma membrane among the AdCMVhCAR-LacZ-infected, the AdCMVLacZinfected and non-infected fibers.
Discussion
In the present study, we showed that rAd-mediated CAR expression made it possible for skeletal muscles to become susceptible to repetitive gene transduction using rAd without influencing muscle membrane integrity. We suggest that co-expression of CAR and a therapeutic gene should be useful for efficient rAd-mediated gene transduction to skeletal muscle and that a combination of this method and previously reported strategies [7] [8] [9] [10] would result in beneficial clinical applications in the future.
Therapeutic gene transfer by rAd to adult skeletal muscle was not as efficient as to neonate. 5, 12 Nalbantoglu et al 14 showed that a maturation-dependent loss of myofiber susceptibility to transduction by rAd depended on the first attachment receptor and that CAR expression in adult mouse muscle was lower than in C2C12 cells and immature skeletal muscle of neonatal, as demonstrated by mRNA detection using RT-PCR. The underlying cause was that the densities of ␣ v ␤ 3 , ␣ v ␤ 5 and ␣ 5 ␤ 1 integrin, secondary entry receptors for adenovirus, were low after muscle maturation. 5 The Feero et al 13 postulated an anatomical barrier of connective tissue, developing during maturation of skeletal muscle tissue, that excluded viruses from the surface of the cell membrane. In some experiments with elevated expression of CAR in mouse and human fibroblasts, the susceptibility to adenovirus infection tended to correlate with CAR expression. 16, 26 Subsequently, C2C12 and primary cultured myoblasts with stable expression of retrovirus-induced CAR cDNA were sensitive for adenovirus infection, in vitro and in vivo.
14 In our present study, we showed a similar effect in the myoblast cell lines using rAd containing CAR cDNA. Furthermore, many fibers in antero-tibialis muscle became susceptive to inoculation with AdCMVhCAR- LacZ, in vivo. The elevated CAR expression made for better susceptibility in mature muscle fibers as well as in immature myoblasts, and could be sufficient for the improvement of gene transducibility utilizing rAd in skeletal muscle. Thus, these are all elements to support rAd-mediated gene transduction except for a first-attachment receptor in skeletal muscle. Therefore, we did not have to examine expression of the ␣ v -containing integrins that were known as the second entry-receptor for aden- ovirus. Although nude mice were injected with first rAd at 7 days after birth, LacZ expression could not be detected far from the injection site over the fascia and perimysium. Because the adenovirus cannot spread over the fascia and perimysium that may be an anatomical barrier cutting off the virus concentration at the membrane surface of the myofiber. It has been suggested that connective tissue and extensive basal lamina surrounding mature myofibers may interfere with the adenovirus vehicle's approach to the sarcolemma of muscle fibers. 13, 14 In addition, sufficient transgene expression has been observed using low concentrations of the second marker virus. The use of a low-titer virus solution may decrease the risks associated with the rAd concentration, since a high titer of rAd has been known to be intrinsically toxic to cells. Our method with rAd-mediated hCAR expression has solved the above-mentioned problems.
Most reports have demonstrated that gene transducibility by rAd in mature muscle fiber is lower than in immature fiber. 5, 14 In addition, the damaged skeletal muscle of rodent models pretreated with notexin 27 have included many more CAR-expressing fibers than untreated controls. In hereditary myopathy, such as Duchenne muscular dystrophy, there are mixed regenerating and degenerating fibers. 28 The regenerating fibers are considered to originate from satellite cells, which can split, increase and fuse as immature myocytes 29 and they can be susceptible to rAd infection. Indeed, CAR has been detected on the surface of regenerating fibers in mdx muscle by immunohistological staining.
14 Therefore, some myoblasts and immature muscle fibers susceptible to rAd can become mature muscle fibers in DMD patients' skeletal muscle. Thus, rAds could be expected to transduce therapeutic genes into DMD muscle at any stage. Upon co-expressing both CAR and a therapeutic 
Figure 4 Immunohistochemical staining for hCAR, dystrophin and ␤-dystroglycan in skeletal muscle membrane expressed with hCAR. Moderate magnified views (1:400) of serial sections from antero-tibialis muscles of nude mice pre-injected with AdCMVhCAR-LacZ (a, b, e, f, i, j, m, n, p and q) AdCMVLacZ (c, g, k and o) or not injected (d, h and l), then stained with anti-hCAR polyclonal antibody (anti-CAR antibody, donated by Dr GE Blair, 1:200), antidystrophin polyclonal antibody (anti-6-10 antibody, donated by TJ Byers and LM Kunkel, 1:1000) and anti-␤-dystroglycan antibody (NCL-43DAG, Novacastra Laboratories, 1:50) as first antibodies, and then further stained with Cy3-conjugated anti-rabbit immunoglobulin (Jackson ImmunoResearch Laboratories, 1:500), or pre-blocked with Mouse to Mouse Block reagent especially and stained with Cy3-conjugated anti-mouse immunoglobulin (Jackson ImmunoResearch Laboratories, 1:500). Scale bar represents 20 m. (a, e and i) are negative controls for (b, f and j) omitting the first antibody and do not show any significant signals. (b, c and d) show localization of forced expression of hCAR, (f, g and h) show localization for dystrophin, and (j, k and l) show the localization of ␤-dystroglycan. The background views of (c and d) are the difference interference contrast (DIC) views. (m) shows GFP expression by second infection with AdRSVEGFP. (n and o) show ␤-galactosidase expression by first infection with AdCMVhCAR-LacZ or AdCMVLacZ. All green scale bars represent 20 m, for (a to o). (p and q) show a high magnified view (1:4000) of one fiber co-expressed with hCAR (p) and GFP (q). Yellow scale bars represent 2.5 m. The hCAR is detected along the sarcolemma of AdCMVhCAR-LacZ-infected fiber (b and p), but not of AdCMVLacZ-infected (c) or non-infected fiber (d). In some fibers infected with many AdCMVhCAR-LacZ, which expressed hCAR and ␤-galactosidase strongly, high signals are detected not only along the sarcolemma but also in the cytosol (b and p). Overexpressed hCAR may exist at the Golgi apparatus or endplasmic reticulum (ER) in cytosol. Furthermore, there are no detectable differences in the presence of dystrophin and ␤-dystroglycan along the plasma membrane among the AdCMVhCAR-LacZ-infected (hCAR positive) (f and j), the AdCMVLacZ (g and k) infected, and non-infected fibers (h and l).
gene, muscle fibers would be normalized and become sensitive to rAd. At the next injection, their transduction efficacy could be expected to be greater than at the first injection. Therefore, we suggest that maintaining CAR expression retains transduction efficacy and normalization, and that the ratio of normalized myofibers would increase as transduction is repeated. Furthermore, we have suggested rAd containing CAR will be safe for gene therapy, because our data showed that elevated CAR expression had no effect on the localization of dystrophin and ␤-dystroglycan; CAR should not obstruct skeletal muscle integrity. The role of CAR remains to be studied to evaluate its physiological function.
To avoid immune reactions to both first-generation rAds 6 and expressed proteins, namely ␤-galactosidase from E. coli, 9 GFP from jellyfish, and human CAR, we used nude mice in this study. If immune reactions to them could be suppressed, our strategy would be applied to gene transduction to immunocompetent hosts. At present, some strategies that protect vectors from the host immune system have been proposed, for example, FK506 immunosuppression agent, 7 CTLA4Ig, 8 a gutted adenovirus vector which produces less protein from adenovirus. [9] [10] [11] Adding our method to these strategies would provide muscles of immunocompetent animals with efficient therapeutic gene expression for a long period.
Materials and methods
Cell culture HEK-293 cells and NIH3T3 cells were maintained as monolayers in Dulbecco's modified essential medium (DMEM; Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS; JRH Biosciences, Lenexa, KS, USA), 50 U/ml penicillin and 50 g/ml streptomycin (Sigma Chemical, St Louis, MO, USA). C2C12 cells were grown in the same conditions and when differentiation was induced the medium was changed to a differentiation medium with 1% FCS. All cells were grown in a humidified incubator with 5% CO 2 at 37°C.
Virus stocks
All four types of rAd in this study were constructed by the COS-TPC method, 30 which were E1 and partial E3 defected vectors based on the Ad5 genome ( Figure 5 ). AdCMVLacZ and AdCMVGFPS65T contain the E. coli LacZ (␤-galactosidase) gene, and mutated green fluorescent protein gene (GFPS65T), respectively. These markers were transcribed under the control of a human cyotomegarovirus immediate-early gene promoter/enhancer and SV40 poly A signal. AdCMVhCAR-LacZ contains the encephalomyocarditis virus' internal ribosomal entry site (IRES) for dual expression of hCAR cDNA and LacZ gene. AdRSVEGFP had an enhanced green fluorescent protein gene (EGFP) under the control of the Rous sarcoma virus immediate-early promoter/enhancer and SV40 poly A signal. These rAds were plaque purified three times and then propagated. For preparation of large purified virus stocks, 4 × 10 8 of 293 cells were infected with the propagated virus and harvested after the cytopathic effect (CPE) became visible around 48 h after infection. Cells were lysed in 0.1 m Tris HCl pH 8.0 containing Gene Therapy Fluorocytometric analysis of C2C12 cells expressing hCAR and GFP Twenty-four hours after the second infection, the remainder of the cells were harvested by trypsinization. Cells were washed with 2% FCS/0.04% sodium azide/PBS (cell suspension buffer), and incubated for 30 min at 4°C, the anti-hCAR monoclonal antibody 15 (RmcB ascites, donated by Dr JM Bergelson, Division of Immunologic and Infectious Diseases, Children's Hospital of Philadelphia, PA, USA) used at 1:1000 dilution. The cells were pelleted by centrifugation, incubated for 30 min at 4°C with the second antibody, biotin-conjugated goat antimouse IgG (Vector Laboratories, Burlingame, CA, USA) used at 1:100 dilution and washed in the cell suspension buffer. Then they were incubated for 20 min at 4°C with Streptavidin-Red 670 (Gibco-BRL, Gaithersburg, MD, USA) used at 1:500 dilution, and washed thoroughly before fluorocytometric analysis. For each sample at least 10 000 living cells, gated to exclude debris and cell clumps, were analyzed for the distribution of single-cell fluorescein fluorescence in a Becton Dickinson FACSCalibur cytometer using CellQuest software (Becton Dickinson). All data were analyzed by the KruskalWallis nonparametric analysis of variance (ANOVA).
X-gal and immunofluorescent staining for C2C12 myotubes For analysis of the efficacy of AdCMVhCAR-LacZ following a second infection of differentiated myotubes, 24 h after the preparation of 2 × 10 4 C2C12 myoblasts on 1.6 cm 2 tissue culture slides (Becton Dickinson), cells were washed and the medium was changed to a differentiation medium with 1% FCS. After 120 h, cells in each of the chambers were inoculated with 1 × 10 6 p.f.u. AdCMVhCAR-LacZ or AdCMVLacZ in 50 l medium at 37°C for 90 min. Twenty-four hours after the first infection, the cells were inoculated with 1 × 10 5 p.f.u. AdRSVEGFP in 50 l of PBS (++) at 37°C for 60 min. After 24 h following the second infection, the cells were stained with X-gal, as described above. Detection of GFP and ␤-galactosidase in muscle cryosections GFP expression in muscle cryosections was detected with a Confocal Laser Scan Microscope (LSM410; Carl Zeiss Microscopy, Jena, Germany), as soon as they were thaw mounted on the glass slides. The section next to each GFP-positive or -negative cell-containing section was stained with X-gal. For X-gal staining, slides were fixed with 4% PFA in PBS at room temperature for 10 min, washed twice with PBS at room temperature for 15 min, and then histochemically stained with 0.1% X-gal in 5 mm potassium ferricyanide, 5 mm potassium ferrocyanide and 2 mm MgCl 2 at 37°C for 6 h. Transduction efficacy was scored by counting the number of GFP and LacZpositive fibers on the serial cryosections through the muscle along the long axis. The data were analyzed statistically using a two-tailed t test.
Immunohistchemical staining for hCAR, dystrophin and ␤-dystroglycan in muscle cryosections We detected the expression of hCAR by rAd, dystrophin, and ␤-dystroglycan, under the surface of muscle fibers so as to prove the fiber's integrity even though hCAR is highly expressed by the rAd. For immunohistochemical staining, the serial sections on slides were fixed with cooled acetone (4°C) for 5 min. After 10 min air drying, the slides were rinsed with 0.1% Triton/PBS (TPBS) at room temperature for 10 min, and blocked with 2% normal goat serum in TPBS for using rabbit polyclonal antibodies. For using mouse monoclonal antibodies, especially for adding, the slides were further blocked with Super block reagent (ScyTeK, West Logan, UT, USA) for 5 min and with Mouse to Mouse block reagent (ScyTeK) in TPBS at room temperature for 15 min and washed with PBS four times. They were then incubated with anti-human CAR rabbit polyclonal antibody 24 (anti-CAR, donated by Dr GE Blair (School of Biochemistry and Molecular Biology, University of Leeds, UK), 1:200 diluted with TPBS), or anti-dystrophin rabbit polyclonal antibody 25 (anti-6-10 antibody, donated by TJ Byers and LM Kunkel (Department of Medicine (Genetics), Howard Hughes Medical Institute, Children's Hospital, Boston, MA, USA), 1:1000), or anti-␤-dystroglycan monoclonal antibody (NCL-43DAG; Novacastra Laboratories, Newcastle upon Tyne, UK, 1:50) at room temperature for 2 h. After washing carefully with TPBS three times for 10 min each, sections were incubated with Cy3-conjugated antirabbit donkey second antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA, 1:500 diluted with TPBS) or Cy3-conjugated anti-mouse goat second antibody (Jackson ImmunoResearch Laboratories, 1:500 diluted with TPBS), respectively, at room temperature for 2 h in a dark room, and then washed carefully with TPBS three times. They were then mounted and observed with a Confocal Laser Scan Microscope (LSM410; Carl Zeiss Microscopy).
